Mckesson stock hits all-time high of 823.6 USD

McKesson Corporation’s stock reached a significant milestone by hitting an all-time high of 823.6 USD. This surge in stock price underscores the company’s robust performance over the past year, marked by a remarkable 62.46% increase. According to InvestingPro data, the healthcare giant has delivered an impressive 42.18% return year-to-date, with a current market capitalization of $100.46 billion. The pharmaceutical distribution giant has been benefiting from strong demand and strategic initiatives, propelling its stock to new heights. This achievement reflects investor confidence and the company’s successful navigation of the evolving healthcare landscape. InvestingPro analysis indicates the stock is trading slightly above its Fair Value, with a "GREAT" overall financial health score. Management has been aggressively buying back shares, one of many insights available in the comprehensive Pro Research Report. As McKesson continues to expand its operations and enhance its service offerings, its stock remains a focal point for market watchers. With analyst price targets reaching as high as $900 and earnings scheduled for release in just 6 days, investors seeking deeper insights can access 18 additional ProTips and extensive financial metrics through InvestingPro, which covers over 1,400 US equities with detailed research reports.

In other recent news, McKesson Corporation announced a regular quarterly dividend of 82 cents per share, payable on January 2, 2026, to shareholders of record as of December 1, 2025. Following the company’s recent Investor Day, several financial firms have adjusted their price targets for McKesson. TD Cowen increased its price target to $864, citing enhanced long-term adjusted earnings per share guidance and higher targets for North America Pharmaceutical and Oncology/multispecialty adjusted operating income. UBS raised its price target to $860, highlighting McKesson’s strong cash flow conversion and strategy of reinvesting in growth markets. Mizuho adjusted its target to $770, noting the company’s raised EPS growth guidance from 12-14% to 13-16%, which addresses investor concerns. Leerink Partners increased its price target to $850, attributing the rise to better-than-expected growth in McKesson’s pharmaceutical segments. These developments reflect a positive outlook from analysts regarding McKesson’s strategic initiatives and financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.